Development & Strategic Solutions

The preclinical stage represents the critical scientific foundation determining IND approval probability and successful clinical program initiation. Beyond generating regulatory compliance data, strategic preclinical development establishes translational rationale, identifies development risks, and optimizes the path to first-in-human studies.

BXPLANT delivers comprehensive preclinical strategies aligned with Target Product Profile (TPP) objectives, indication-specific requirements, and global regulatory standards (FDA, EMA, MFDS, PMDA). From study design and GLP oversight to translational pharmacology and regulatory package assembly, we provide scientifically justified decision-making frameworks that maximize IND success probability and optimize downstream clinical performance.

PK/PD modeling and simulation (M&S) is a cornerstone of Model-Informed Drug Development (MIDD), enabling quantitative assessment of dose-exposure-response relationships to reduce clinical trial uncertainty, optimize dose selection, and increase Probability of Technical Success and Clinical Success.

BXPLANT’s comprehensive PK/PD M&S platform bridges the translational gap between preclinical discovery and clinical proof-of-concept. By integrating in vitro and in vivo preclinical data with mechanistic and empirical modeling approaches—including physiologically-based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology (QSP), population PK/PD analysis, and AI-augmented simulations—we deliver high-confidence predictions of human PK, PD, efficacy, and safety before first-in-human (FIH) dosing. By applying fit-for-purpose modeling strategies throughout the development lifecycle, BXPLANT’s MIDD expertise accelerates decision-making, reduces clinical trial failures, and maximizes the value of your development portfolio in alignment with ICH E4, FDA MIDD guidance, and EMA modeling and simulation frameworks.

Our MIDD solutions encompass:

Preclinical to Clinical Translation

▸Allometric scaling and PBPK modeling for human PK prediction

▸Minimal anticipated biological effect level (MABEL) and maximum recommended starting dose (MRSD) determination

▸Human dose projection using preclinical efficacy and safety margins

Clinical Trial Optimization

▸Virtual trial simulations for sample size determination and adaptive design

▸Dose-ranging study optimization and exposure-response modeling

▸Covariate analysis for special populations (pediatrics, renal/hepatic impairment, drug-drug interactions)

Regulatory Strategy & Submissions

▸Model-based meta-analysis for competitive landscape assessment

▸Integrated safety and efficacy analyses aligned with FDA, EMA, and MFDS guidance

▸Clinical pharmacology briefing packages and End-of-Phase 2 Meeting preparation

Post-Approval Lifecycle Management

▸Label expansion modeling for new indications and populations

▸Real-world evidence (RWE) integration with population PK/PD frameworks

▸Pharmacometric support for post-marketing commitments

Clinical success is determined not by execution alone, but by the strategic architecture underlying development programs. Optimized clinical strategies that balance scientific rigor, regulatory requirements, and commercial objectives deliver accelerated timelines, capital efficiency, and de-risked approval pathways.

BXPLANT provides comprehensive strategic consulting across the full development continuum—from Target Product Profile (TPP) and Clinical Development Profile (CDP) definition and competitive landscape assessment through clinical program design, regulatory pathway optimization, and market access planning. Our tailored consulting maximizes asset value, strengthens investment positioning, and increases the probability of technical and regulatory success.

The Clinical Project Lead serves as the strategic command center orchestrating cross-functional alignment between clinical strategy and operational execution. Beyond project management, the CPL role demands therapeutic expertise, regulatory acumen, and proactive risk management to navigate complex development programs while ensuring quality, timeline, and budget adherence.

BXPLANT’s CPL service operates as an extension of your clinical organization—providing integrated leadership across project objectives, resource allocation, vendor management, and quality oversight. Through comprehensive operational command and seamless stakeholder coordination, we ensure protocol fidelity, operational excellence, and maximize probability of study success.